Holen Sie sich die Stockscreener-App
65.40
6.40%
3.87
Schlusskurs vom Vortag:
$61.53
Offen:
$62.87
24-Stunden-Volumen:
281.39K
Relative Volume:
0.46
Marktkapitalisierung:
$1.39B
Einnahmen:
$56.54M
Nettoeinkommen (Verlust:
$-30.70M
KGV:
-167.69
EPS:
-0.39
Netto-Cashflow:
$-31.05M
1W Leistung:
+25.28%
1M Leistung:
+45.65%
6M Leistung:
+200.32%
1J Leistung:
+470.30%
1-Tages-Spanne:
$61.00
$65.69
1-Wochen-Bereich:
$51.69
$65.53
52-Wochen-Spanne:
$10.14
$65.53
Cidara Therapeutics Inc Stock (CDTX) Company Profile
Firmenname
Cidara Therapeutics Inc
Sektor
Branche
Telefon
858-752-6170
Adresse
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Vergleichen Sie CDTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CDTX
Cidara Therapeutics Inc
|
65.28 | 1.14B | 56.54M | -30.70M | -31.05M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.04 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.83 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.11 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.91 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.75 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-03-12 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-01-27 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-12-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-11-08 | Eingeleitet | Guggenheim | Buy |
| 2024-08-14 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-12-03 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-09-22 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2021-03-04 | Eingeleitet | Aegis Capital | Buy |
| 2019-09-04 | Hochstufung | Wedbush | Neutral → Outperform |
| 2018-07-26 | Eingeleitet | Citigroup | Buy |
| 2017-04-21 | Eingeleitet | Raymond James | Strong Buy |
| 2017-04-17 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-12 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-04-11 | Fortgesetzt | Wedbush | Outperform |
| 2017-02-22 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-22 | Hochstufung | WBB Securities | Sell → Hold |
| 2016-12-21 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-09-23 | Herabstufung | WBB Securities | Hold → Sell |
| 2015-10-09 | Hochstufung | WBB Securities | Sell → Hold |
| 2015-05-11 | Eingeleitet | Jefferies | Buy |
| 2015-05-11 | Eingeleitet | Leerink Partners | Outperform |
| 2015-05-11 | Eingeleitet | Needham | Buy |
| 2015-05-11 | Eingeleitet | Wedbush | Outperform |
| 2015-04-23 | Eingeleitet | WBB Securities | Sell |
Alle ansehen
Cidara Therapeutics Inc Aktie (CDTX) Neueste Nachrichten
Is Cidara Therapeutics Inc. a good long term investmentMarket-beating returns - Autocar Professional
Cidara more than doubles on phase 2 flu preventative data - MSN
What analysts say about Cidara Therapeutics Inc. stockHigh-yield portfolio picks - jammulinksnews.com
(CDTX) On The My Stocks Page - news.stocktradersdaily.com
What drives Cidara Therapeutics Inc. stock priceBreakthrough profit margins - jammulinksnews.com
ATAI Impresses, CDTX Navigates With Confidence, MTSR Builds Momentum, COGT Keeps Scaling The Summit… - RTTNews
Cidara Therapeutics Inc. Stock Analysis and ForecastFree Predictions - jammulinksnews.com
Growth or Bubble? Unpacking CDTX Stock Surge - timothysykes.com
Cidara Therapeutics stock hits 52-week high at 56.85 USD - Investing.com India
Cidara Therapeutics stock hits 52-week high at 56.85 USD By Investing.com - Investing.com Nigeria
Cidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Average Rating of “Buy” from Brokerages - Defense World
What makes Cidara Therapeutics Inc. stock price move sharplyWatchlist Winner Update - Newser
Why Cidara Therapeutics Inc. stock attracts strong analyst attentionConsistent Growth Alert - newser.com
Finance Watch: A Mini-Surge In Follow-On Offerings Follows Positive Updates - insights.citeline.com
Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics - Business Wire
Cidara Therapeutics announces inclusion in the Russell 2000 and 3000 indexes - MSN
Cidara Therapeutics shares rise 1.47% premarket after granting inducement awards to new employees. - AInvest
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Cidara Therapeutics shares fall 5.99% after-hours following inducement grants announcement. - AInvest
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains - TradingView
hVIVO reports positive results from Cidara’s Phase 2b influenza study By Investing.com - Investing.com Canada
(CDTX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Phathom Pharmaceuticals shares rise 1.47% premarket after Cidara Therapeutics closes $402.5 million stock offering. - AInvest
Cidara Therapeutics prices upsized $350 milion stock offering at $44 - MSN
Cidara Therapeutics Prices $350 Million Public Offering - MarketScreener
Cidara Therapeutics (CDTX) Price Target Raised by RBC Capital | CDTX Stock News - GuruFocus
Cidara Therapeutics announces $250M public stock offering - MSN
Cidara stock surges as H.C. Wainwright raises price target on trial data By Investing.com - Investing.com South Africa
Cidara Therapeutics Stock Jumps After-Hours As Strong Flu Trial Data Outweighs $250M Share Offering - MSN
Form 424B5 Cidara Therapeutics, - StreetInsider
Cidara Therapeutics (CDTX) to Launch $250M Public Offering | CDT - GuruFocus
Cidara Therapeutics plans $250 million common stock offering By Investing.com - Investing.com Canada
Cidara Therapeutics (CDTX) Price Target Boosted Following Positi - GuruFocus
Cidara Therapeutics (CDTX) Receives Strong Buy Rating from WBB Securities | CDTX Stock News - GuruFocus
Cidara Therapeutics Stock Rises as Strategic Partnerships Strengthen Position - timothysykes.com
Cidara Therapeutics Announces Positive Topline Results From Its Phase 2B Navigate Trial - TradingView
Cidara Therapeutics stock rockets after positive flu prevention trial results By Investing.com - Investing.com UK
Cidara Therapeutics Approves Key Amendments at Annual Meeting - TipRanks
(CDTX) Proactive Strategies - news.stocktradersdaily.com
Cidara Therapeutics (CDTX) Receives Buy Rating from HC Wainwrigh - GuruFocus
H.C. Wainwright assumes coverage on Cidara stock with buy rating By Investing.com - Investing.com UK
H.C. Wainwright Initiates Coverage on Cidara Therapeutics (CDTX) with Strong Outlook | CDTX Stock News - GuruFocus
Cidara Therapeutics (NASDAQ:CDTX) Given Overweight Rating at Cantor Fitzgerald - Defense World
Cidara Therapeutics (CDTX) Reiterates Overweight Rating by Canto - GuruFocus
(CDTX) Investment Analysis - news.stocktradersdaily.com
Millennium Management LLC Raises Stock Holdings in Cidara Therapeutics, Inc. (NASDAQ:CDTX) - Defense World
Citizens JMP Reaffirms Their Buy Rating on Cidara Therapeutics (CDTX) - The Globe and Mail
Cidara Therapeutics stock maintains strong rating at Citizens JMP By Investing.com - Investing.com Canada
Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $36.00 at Needham & Company LLC - Defense World
Insider Buying: Chrysa Mineo Acquires Shares of Cidara Therapeutics Inc (CDTX) - GuruFocus
Needham raises Cidara Therapeutics stock price target to $36 - Investing.com
Finanzdaten der Cidara Therapeutics Inc-Aktie (CDTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cidara Therapeutics Inc-Aktie (CDTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mineo Chrysa | Director |
Jun 02 '25 |
Buy |
21.71 |
2,270 |
49,281 |
2,270 |
| Mineo Chrysa | Director |
Jun 03 '25 |
Buy |
23.44 |
1,050 |
24,614 |
3,320 |
| Ward Shane | COO & CLO |
Mar 11 '25 |
Sale |
21.96 |
1,664 |
36,542 |
14,674 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Mar 11 '25 |
Sale |
21.96 |
1,773 |
38,940 |
16,215 |
| Sandison Taylor | Chief Medical Officer |
Sep 11 '24 |
Sale |
11.64 |
924 |
10,752 |
23,067 |
| Tari Leslie | CHIEF SCIENTIFIC OFFICER |
Sep 11 '24 |
Sale |
11.64 |
909 |
10,580 |
17,788 |
4.11%
0.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):